Form 4: Dianthus Therapeutics Director Simon Read Acquires 25,000 Stock Options

Director Simon Read of Dianthus Therapeutics acquires 25,000 stock options at an exercise price of $18.36 on May 22, 2025.

Summary

• On May 22, 2025, Simon Read, a director of Dianthus Therapeutics, acquired 25,000 stock options.
• The exercise price for these options is $18.36.
• The options vest in three equal installments on the first, second, and third anniversaries of the grant date, contingent upon continued service to the issuer.
• The expiration date for the options is May 22, 2035.

Sentiment

Score: 5

Explanation: This is a neutral event, simply reporting a stock option grant. It doesn't inherently indicate positive or negative sentiment.

Future Outlook

The vesting of the stock options is contingent upon the Reporting Person's continued service to the Issuer.

Industry Context

This is a standard Form 4 filing, reflecting a change in beneficial ownership of securities by a company insider. It's a routine part of corporate governance and transparency requirements.

Stakeholder Impact

• The stock option grant aligns the director's interests with those of the shareholders, incentivizing them to increase the company's value.

Key Dates

Keywords

stock options, Dianthus Therapeutics, director, Simon Read, Form 4, beneficial ownership, equity securities